Oct. 01, 2021 8:59 AM ETTimber Pharmaceuticals, Inc. (TMBR)By: Mamta Mayani, SA News
Timber Pharmaceuticals (NYSE:TMBR) presents results from Phase 2a study evaluating TMB-001 in patients with lamellar or X-linked congenital ichthyosis (CI) at EADV 2021 congress.The study demonstrated no concerning safety signals and no evidence of significant systemic exposure to isotretinoin or tretinoin after 12 weeks of treatment.
Most participants in the study experienced ≥1-grade Investigator Global Assessment (IGA) score reduction and improvement in clinical signs and symptoms of moderate or severe CI.
Importantly, patients experienced ≥75% improvement of one point from baseline in scaling by IGA measurement and 100% of TMB-001 treated patients were considered to have had their scaling clear, almost clear, or mild by day 57.
Timber also has an ongoing Phase 2b clinical trial, called the CONTROL study, of TMB-001 in CI and expects to report topline data in Q4 2021. Also, the company is planning for an end-of-Phase 2 meeting with the FDA by year end. CI is a group of rare, genetic keratinization disorders that lead to dry, thickened, and scaling skin.